CD200AR Ligands for Reversing Tumor-Induced Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for malignant glioma, are inadequate due to immune suppression by tumors, leading to low survival rates and resistance to immune checkpoint inhibitors.
Innovation Solution
Targeting the CD200 checkpoint with CD200 activation receptor ligands (CD200AR-L) to downregulate inhibitory receptors like CD200R1 and PD-1, enhancing immune cell activation and overcoming suppressive pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cell activation is enhanced to improve anti-tumor immunity, then cancer immunotherapy efficacy is improved, but autoimmunity and off-target effects worsen
Solution Approach 1:
The patent applies local quality by making the T cell activation specific to certain tissue contexts through tissue-restricted antigens (TRAs). The Cd200ar ligands are expressed specifically in certain tissues (such as lung, liver, and kidney) rather than universally, which allows T cells to be activated only in those specific locations where the TRA is present, thereby enhancing anti-tumor immunity in affected tissues while preventing widespread autoimmunity and off-target effects in healthy tissues.
Solution Approach 2:
The patent uses tissue-restricted antigens (TRAs) as intermediaries to mediate between the immune system and tumor cells. These TRAs are expressed on tumor cells and certain normal tissues but not on healthy non-target tissues. The Cd200ar ligands bind to these TRAs, serving as a mediator that directs T cell activation specifically to tumor cells expressing the TRA while sparing healthy tissues that do not express the target antigen, thus resolving the contradiction between efficacy and safety.
2Reliability
If T cell activation is enhanced to improve anti-tumor immunity, then tumor cell killing is improved, but tissue damage worsens
Solution Approach 1:
The patent applies local quality by restricting T cell activation to specific tissues where the tissue-restricted antigen is expressed. The Cd200ar ligands are expressed in a tissue-specific manner (e.g., lung, liver, kidney), which confines the immune response to those specific locations. This ensures that tumor cells expressing the TRA are killed effectively while healthy tissues that do not express the target antigen are protected from damage.
Solution Approach 2:
The patent inverts the traditional approach by using tissue-restricted antigens that are expressed on both tumor cells and certain normal tissues, but by controlling the activation through Cd200ar ligand presentation, it achieves selective killing. The inversion lies in using an antigen that is not exclusively tumor-specific but achieving tumor-selective killing through the controlled presentation mechanism of Cd200ar, thereby improving tumor cell killing while minimizing off-target tissue damage.
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 2D~3A
AI summary
The present invention in certain embodiments provides a method of inhibiting PD-1 in a cell by administering a CD200 activation receptor ligand (CD200AR-L) to the cell. The present invention in certain embodiments provides a method of enhancing efficacy of a tumor lysate vaccine in a mammal comprising administering a CD200 activation receptor ligand (CD200AR-L) to the mammal prior to the administration of the tumor lysate vaccine.